Silexion Clears Key Regulatory Hurdle for SIL204 Pancreatic Cancer Trial
Event summary
- Silexion Therapeutics received unconditional approval from Germany's BfArM to initiate a Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer.
- The approval follows similar clearance from Israel, positioning Silexion to start dosing patients in the coming weeks.
- The trial will evaluate SIL204 in combination with standard chemotherapy using a dual-route administration strategy.
- Pancreatic cancer has a five-year survival rate below 13%, with KRAS mutations present in approximately 90% of cases.
The big picture
Silexion's approval from Germany's BfArM, known for its rigorous standards, validates the preclinical and safety package of SIL204. This milestone positions Silexion to address one of oncology's most persistent challenges: KRAS-driven pancreatic cancer. The trial's success could set a precedent for RNAi therapies in targeting other KRAS-mutated cancers.
What we're watching
- Trial Execution
- The pace at which Silexion can initiate dosing and complete site activation in Israel and Germany will determine the trial's timeline.
- Regulatory Expansion
- Whether Silexion can leverage this approval to expand the Phase 2/3 program across additional EU member states under the harmonized CTIS framework.
- Clinical Efficacy
- How SIL204's dual-route administration strategy performs in combination with standard chemotherapy against a disease with high unmet medical need.
Related topics